Patrys Receives $3.35m R&D tax incentive refund
- Patrys (PAB) subsidiary Nucleus Therapeutics receives a $3.35 million research and development tax incentive refund from the Australian Federal Government
- The funds are for R&D undertaken during the 2021/2022 financial year
- The company CEO and Managing Director James Campbell says the company is “extremely grateful” for the support the government provides to the Australian biotech industry
- This rebate, in combination with Pat rys’ existing cash balance, will enable the company to continue advancing its treatments for a range of cancers in the second half of 2023
- The company is down 3.13 per cent and trading at 3.1 cents at 2:32 pm AEDT
